Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · IEX Real-Time Price · USD
38.52
-1.57 (-3.92%)
At close: Apr 16, 2024, 4:00 PM
38.57
+0.05 (0.13%)
After-hours: Apr 16, 2024, 4:33 PM EDT
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RYTM stock have an average target of 47.4, with a low estimate of 27 and a high estimate of 55. The average target predicts an increase of 23.05% from the current stock price of 38.52.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RYTM stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 3 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +29.80% | Apr 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +29.80% | Feb 22, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $42 → $52 | Strong Buy | Maintains | $42 → $52 | +34.99% | Jan 26, 2024 |
| Needham | Needham | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +29.80% | Jan 26, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $42 → $52 | Strong Buy | Maintains | $42 → $52 | +34.99% | Jan 25, 2024 |
Financial Forecast
Revenue This Year
137.65M
from 77.43M
Increased by 77.78%
Revenue Next Year
212.76M
from 137.65M
Increased by 54.57%
EPS This Year
-4.19
from -3.20
EPS Next Year
-2.05
from -4.19
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 156.6M | 323.4M | 505.1M | 979.8M | 1.7B |
| Avg | 137.7M | 212.8M | 379.7M | 717.6M | 1.2B |
| Low | 113.3M | 161.4M | 253.0M | 515.1M | 882.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 102.2% | 134.9% | 137.4% | 158.0% | 134.5% |
| Avg | 77.8% | 54.6% | 78.5% | 89.0% | 71.5% |
| Low | 46.3% | 17.3% | 18.9% | 35.7% | 22.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.30 | -0.69 | 2.15 | 6.62 | 13.95 |
| Avg | -4.19 | -2.05 | -0.03 | 4.35 | 11.92 |
| Low | -4.85 | -3.76 | -2.16 | 0.47 | 9.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 221.1% |
| Avg | - | - | - | - | 174.3% |
| Low | - | - | - | - | 127.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.